Evidence map›Paper›PMID 36212092›Full record

ArticleGynecologic oncology reports2022

Pure ovarian dysgerminoma in a postmenopausal patient: A case report and review of the management.

Jennifer Vaz, Alexandra Mulliken, Nivin Omar, Jessa Suhner, Bogna Brzezinska, Thomas Cotter, Patel Nikhil, Robert V Higgins, Bunja Rungruang

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jennifer VazDivision of Gynecologic Oncology, Medical College of Georgia at Augusta University, Augusta, GA, United States.
Alexandra MullikenDivision of Gynecologic Oncology, Medical College of Georgia at Augusta University, Augusta, GA, United States.
Nivin OmarPathology Department, Medical College of Georgia at Augusta University, Augusta, GA, United States.
Jessa SuhnerDivision of Gynecologic Oncology, Medical College of Georgia at Augusta University, Augusta, GA, United States.
Bogna BrzezinskaDivision of Gynecologic Oncology, Medical College of Georgia at Augusta University, Augusta, GA, United States.
Thomas CotterPathology Department, Medical College of Georgia at Augusta University, Augusta, GA, United States.
Patel NikhilPathology Department, Medical College of Georgia at Augusta University, Augusta, GA, United States.
Robert V HigginsDivision of Gynecologic Oncology, Medical College of Georgia at Augusta University, Augusta, GA, United States.
Bunja RungruangDivision of Gynecologic Oncology, Medical College of Georgia at Augusta University, Augusta, GA, United States.
Augusta University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: A pure ovarian dysgerminoma in a postmenopausal female is a rare phenomenon. Case: A 65-year-old female presented with a large pelvic mass. Following surgical debulking, the patient was diagnosed with FIGO Stage IIB ovarian dysgerminoma. She was treated with three cycles of etoposide and cisplatin and has been disease-free for 12 months. Conclusion: Dysgerminomas in postmenopausal females are uncommon. Gynecologic oncologists should be familiar with the pathological diagnosis and treatment recommendations to achieve optimal outcomes.

Indexed as

Germ cell tumorOvarian germ cell tumorPure ovarian dysgerminoma

Identifiers

PMID36212092
PMCPMC9535265
OpenAlexW4296311602

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.